The sequencing boom and the China’s burgeoning healthcare market were major topics of interest at the annual JP Morgan Healthcare Conference earlier this month. WuXi NextCODE looks forward to addressing these evolving topics further in the upcoming BIO CEO and Investor Conference in New York in February, BioCentury “Future Leaders” conference in New York in March, and Cowen & Co. Healthcare Conference in Boston in March.

Like thousands of people across the biotech, pharma, and healthcare industries, we started the year with an intense and very productive week at the annual JP Morgan Healthcare Conference. As ever, we were very pleased to meet with so many colleagues and partners—old, new, and future—and to speak to a truly packed audience during our presentation at the conference. We have returned to work excited for some of the trends in genomics that are clearly in the air.

It was no surprise to us that the sequencing boom was again one of the hot topics for 2018. The bigger question among healthcare experts was, “What companies will be riding this wave, and how will they harness the data to move the needle across healthcare?” Another interesting trend was growing recognition of how large, fast-growing, and innovative China’s healthcare market has become. That’s no surprise either, as China is actively working to become a leader in this field, and its healthcare market is now expected to grow to around $1 trillion by 2020.

WuXi NextCODE is playing a significant role in the evolution of both these fields. One of our main focuses is building our partnerships to ensure that our database management system continues to develop as the global standard. That, and our portfolio of products in China, are poised to play a key role in helping China vault to the fore of genomic medicine.

Regarding sequencing, a lot of the buzz at JP Morgan was around sales figures for instruments. Analysts have estimated that the world market for next-generation sequencing could reach more than $21 billion by 2025. But the challenges in sequencing have moved far beyond the original issues of speed and cost. Now, those at the forefront of the field are focusing on improving accuracy, integrating multi-omic and clinical data, and using advanced analytics to apply that data to healthcare challenges. High-throughput sequencing is flourishing in industry, academia, non-profits, and medical practice. The goals are to improve current treatment outcomes and to find new drugs and diagnostics.

Prominent sequencing instrument providers, such as Illumina, are bellwethers of this market. Analysts attributed that company’s current healthy sales to factors that include: the growth of the consumer genetics market, the continued rise of targeted cancer therapies, increasing numbers of countries pursuing large-scale genomic studies, advances in sequencing to diagnose rare diseases, uptake of non-invasive prenatal testing, and the dawn of liquid biopsies. We have leading and innovative offerings in all of these areas.

The recognition of China’s emergence as a major healthcare market also resonated with the Wuxi NextCODE team. In another recent report, Cannaccord analyst Mark Massaro pointed specifically to increased sales in China of Illumina’s sequencers as one of the factors influencing that company’s currently rosy outlook. He also highlighted our positioning to drive genomics forward there.

Many life sciences companies are starting to see the potential of China’s healthcare market, and Chinese healthcare providers are eager to provide the highest level of care possible. We at WuXi NextCODE have been privileged to be at the frontier of genomic medicine globally, but particularly in China, where we have multiple partnerships with leading hospitals and are quickly expanding our laboratory and sales presence. The breadth and promise of our work in China was recently highlighted in a roundup coming out of JP Morgan.

I’m sure that both sequencing and China’s healthcare marketplace will evolve further over this year and will be major stories again in the weeks and months ahead. And we’ll be telling our part of the story soon at the BIO CEO and Investor conference, BioCentury’s Future Leaders conference, and the Cowen & Co. Healthcare conference.

We look forward to seeing many of you there!

Presenters from Boston Children’s Hospital and Iceland’s deCODE genetics detailed the impact of sequence-based diagnosis of rare disease at WuXi NextCODE’s “Genomes for Breakfast” series at ASHG17.

My last post described work on rare diseases at Children’s Hospital of Fudan University (CHFU) in China, but at our recent “Genomes for Breakfast” series at ASHG17, we also heard about the impact of sequence-based diagnosis of rare disease from colleagues in Boston and Iceland.

From our longstanding partners at Boston Children’s Hospital (BCH), we heard a detailed discussion of how sequencing hundreds of people across numerous families, and the analysis of all that data together, was accelerating our understanding of one disease: nemaline myopathy. That was presented by Alan Beggs of BCH’s Division of Genetics and Genomics, and the Manton Center for Orphan Disease Research at BCH/Harvard Medical School.

A myopathy is a disorder affecting the skeletal muscles. Typical symptoms of congenital myopathies include early onset of hypotonia and weakness, which reflect distinctive pathologic changes in the muscle fibers. There are multiple subtypes of myopathy. Nemaline myopathy is the most common subtype. It can cause painful contortions (arthrogrypothis), make patients dependent on ventilators and wheelchairs or, in less acute forms, lead to mild weakness that can still impair mobility.

One of the biggest challenges in understanding these myopathies is that they are heterogeneous in every way—clinically, pathologically, and genetically. There are multiple genes associated with different subtypes, and they are sometimes shared but can also be completely distinct. Scientists have also found multiple patterns of inheritance even for a single gene.

To try to shed light on this genetic puzzle, Beggs and colleagues have been looking in detail at the particular mutations found in certain patients and mapping those against their symptoms and inheritance patterns. Recently, the researchers sequenced 857 patients with several subtypes, including just over 300 with nemaline myopathy. The BCH researchers are using a variety of sequencing approaches, including exome analysis, RNA sequencing, and whole-genome sequencing (WGS). This is necessary, they have found, because there are unusual variants that are difficult to identify with traditional tools.

Using this array of sequencing technologies and WuXi NextCODE’s clinical interpretation and case-control research tools, they were able to identify specific genetic variants that have already been associated with certain subtypes, identify new variants, and start to predict the clinical impact of each mutation or constellation of mutations. These tools are able to instantly draw upon a wealth of data from BCH, WuXi NextCODE’s knowledge base, and public databases.

The picture that emerges is complex: a large set of variants that sometimes overlap across multiple subtypes, but sometimes are just strongly associated with a single subtype. The NEB gene is of particular interest because it is so strongly associated with nemaline myopathy and quite a bit is known about its biology. Based on these studies, Beggs and his colleagues have also suggested a more accurate approach to diagnosing nemaline myopathy. All of these are steps that benefit patients and their care, and they provide the first step toward developing new and more effective ways of treating these conditions.

The third country represented at our second breakfast was Iceland. Patrick Sulem, who leads the clinical team at deCODE genetics in Reykjavik, presented. Like our collaborators in Shanghai and Boston, but armed with a truly unique set of resources and expertise, the deCODE scientists have made significant strides in better diagnosing rare diseases in children.

The deCODE database is unique in many ways and powered to uncover rare disease-causing variants. It includes the directly sequenced whole genomes of nearly 50,000 Icelanders and 10,000 others; imputed whole genome data on some 400,000 Icelanders; and SNP data from nearly a million people around the world. This gives deCODE allelic frequency data of unrivaled detail. As we have shown, this data can be helpful in diagnosing disease around the world—but when used in Iceland itself, it can point straight to pathogenic mutations and provide a map to wherever they lie in the population.

These strengths are based on some advantages of the population approach, some that others would like to replicate, others that are tough to match. Iceland’s population participates in genetics studies at a higher rate than that of any other country; Iceland has a long, strong tradition of preserving ancestry records and so has a nearly complete national genealogy for the modern era; and a national health system with a centralized record system. These ingredients have given deCODE the right data to find important variants in diseases that have baffled others. (For more details, read my post on Kari Stefansson’s headlining talk for our breakfast series.)

Based on deCODE’s work, it is now evident that whole-genome sequencing (WGS) can greatly improve diagnosis and clinical management of infants and children with hard-to-diagnose diseases. Like their peers at BCH and CHFU, researchers in Iceland have been able to use genomic screenings not just for better diagnoses—giving parents at least the comfort of knowing what’s wrong—but also, in some cases, they have been able to offer better guidance for the children’s treatment.

One such case was the result of the early application of our technology, before NextCODE had spun out of deCODE. It involved two sisters who had undergone a diagnostic odyssey of several years. With whole-genome sequence data from them and their parents, and with the ability to filter allelic frequency data in the context of different modes of inheritance, we were able to identify the culprit variant—a previously unknown variant causing Brown Vialetto Van Laere syndrome—in a matter of minutes. Because the variant was disrupting a riboflavin transporter gene, the diagnosis immediately suggested riboflavin therapy, a course of treatment that halted the progression of their disease.

Finally, it is important to note that the identification of rare disease variants is a promising avenue for feeding drug discovery—not just for the rare conditions themselves, but also potentially for much more common conditions, of which rare diseases can be extreme versions. Solving rare disease is a challenge for us all—indeed, it is a common challenge in the truest sense. The more diagnostics we do, the bigger our databases all over the world, and with the informatics and tools to mine all this data, the more benefits we can deliver to people around the world.

In just one year, Fudan Children’s Hospital and WuXi NextCODE have diagnosed 11,000 pediatric patients in China and created a program that rivals the largest labs in the U.S.

Children’s Hospital of Fudan University (CHFU) in Shanghai is widely considered China’s top pediatric hospital. The doctors there see almost 2.5 million patients annually.

One short year ago, WuXi NextCODE and Fudan launched sequence-based rare disease

testing at CHFU using WuXi NextCODE’s RareCODE test and backed by our knowledgebase and the collective expertise of both organizations. In this first year, an astonishing 11,000 patients received sophisticated genomic screening tests to help guide treatment for hard-to-diagnose, or rare, diseases. One-third of those patients got a precise diagnosis, matching the best rates anywhere in the world. In short, Fudan and WuXi NextCODE have, in just one year, effectively launched the field of sequence-based rare disease diagnostics in China and created a program that rivals the largest labs in the U.S.

We had the distinct pleasure of hearing directly from doctors handling these cases and scientists building the database supporting this collaboration at our recent ASHG breakfast, “Using NGS to diagnose rare disease—experiences from three continents.” Dr Lin Yang, MD, PhD, a clinician at CHFU’s National Children’s Medical Center, presented the hospital’s experience with this rapidly expanding new program.

The service was created thanks to the unique partnership established between the hospital and WuXi NextCODE. WuXi NextCODE contributes its know-how in clinical-grade genomic sequencing, massively scalable informatics, and RareCODE test, backed the most powerful interpretation tools and clinical genetics expertise available.

CHFU, meanwhile, brings to bear the services, knowledge, and skill of its pediatric specialists and the national center of excellence in pediatric medicine housed at the hospital. Notably, CHFU’s Institute for Pediatric Research had previously developed more than 100 tests for single-gene genetic diseases, established multidisciplinary teams of clinical experts to address rare disease, and is among the very first hospitals in China to adopt next-generation sequencing.

Armed with our IT, knowledgebase, and diagnostic tools, this pioneering collaboration has advanced a national center of excellence for diagnosis, treatment, and further medical genetic research. At its core are not just the expertise of both teams, but also a rapidly growing database of mutations causing rare diseases, which the team hopes to grow into the largest in China, and perhaps the world.

Just over 5.5% of babies in China are born with some type of evident syndrome or birth defect. There, as elsewhere, these can impact the skeleton, metabolism, nervous system, circulation, respiration, digestion, and more. These can also be very complex, with multiple phenotypes or overlapping disorders. Some of these are due to causes other than genetics. But a large proportion represent genetic syndromes, of which many are de novo or have never been seen, or at least written about, by other clinical groups.

CHFU started doing single-gene sequencing to help resolve such cases as early as 2010. By 2012 the hospital was also running array CGH, and in 2013 it launched a number of panel tests and an NGS data-analysis pipeline. This history of pioneering genetic analysis put the hospital at the forefront of medical genomics. And things really moved forward fast after CHFU created a joint molecular diagnostic laboratory with WuXi NextCODE.

The two groups confer weekly on difficult cases and, as of now, they have completed some 12,000 genome analyses in just one year, providing a diagnosis in 33% of cases. These include the smallest patients, from the neonatal intensive care unit (NICU)—more than 2,200 of whom received focused exome sequencing and analysis. Just over 13% of those infants received a diagnosis. This lower rate of diagnosis among newborns reflects the greater challenge of working with patients whose signs and symptoms are just appearing. But this number is rising and, as the NICU is a first-tier clinical setting, every diagnosis can be a lifesaver.

Parents and other family members are also often sequenced to determine if the mutations are passed down or have occurred spontaneously (i.e., are de novo). All of that data is incorporated into a database, helping to grow knowledge about the mutations that cause rare diseases.

While there is no specific treatment for most of the syndromes identified, there is an improving picture for a growing number. Patients may receive a lifesaving, or life-changing, treatment plan, or referral to specialists based on their anticipated future needs. Regardless, it is important for the family and doctors to understand as much as possible about what the problem is. It is also helpful for parents and relatives to know that there are potentially pathogenic mutations that run in the family.

At ASHG, our head of communications, Edward Farmer, sat down with Dr Yang, other scientists and physicians from CHFU, and our CSO, Jeff Gulcher, to talk about the growth of the WuXi NextCODE joint rare disease lab and some of its early successes. I’ll be posting Dr Farmer’s interview with them here in the days ahead, so be sure to check back and learn more about the launch of rare disease testing in China.

In an interview with WuXi AppTec’s WXpress news site, WuXi NextCODE CEO, Hannes Smarason, summarizes how genomics AI can make drug development better, faster, and cheaper.

How will WuXi NextCODE bring AI to the forefront of drug discovery and development? I mapped that out recently in an interview with WuXi AppTec’s WXpress news site. Below, I summarize some of the key points from the article.

Our advantage
The core of our strategy is to bring together three different things: Cutting-edge algorithms, domain expertise, and large data sets.

Executing on the strategy
Because of our history pioneering this field, we already have a wealth of samples as well as a very sophisticated and robust way of mining that data to help discover novel treatment pathways and for possibly re-purposing drugs. We are also continually developing new algorithms and other methods to distinguish between people who will respond and those who won’t when given a particular treatment.

The benefits of AI for drug development
Incorporating AI creates a much more data-driven rather than hypothesis-driven process. That improves the likelihood of identifying patterns and novel insights that may have been overlooked using conventional methods. That means finding the truly causal genes or pathways that drive disease. The goal is to have a more powerful starting point for the development of treatments.

Early validation
Our deep-learning algorithms have already been used to uncover a particular mechanism that appears to be a key driver in the development of the vascular system. That mechanism had not previously been described. Yale biologists then validated that discovery in an animal model, proving that our AI method had accurately predicted the role of this particular pathway in vascular development. So, when used correctly, AI can open up a whole new druggable pathway.

Challenges and hurdles
We must look at AI as a force-multiplier, as opposed to a replacement for independent thinking. That’s one reason having domain expertise in genetics and biology is absolutely key. The second thing is that you have to have access to a wealth of information, including cohort studies as well as genomic and phenotypic data.

The role of AI in evolving drug discovery and development?
Much like any major technological development, it’s going to start up slowly and then gather momentum. We believe that because of AI’s unique ability to bring large and complex data sets together and identify patterns within them, that in the end, it’s going to have an exponential impact in advancing and applying precision medicine. The result is going to be game-changing benefits to patients around the globe in terms of better diagnostics and better-targeted drugs.

Read the full interview.

At the second WuXi NextCODE “Genomes for Breakfast” session at ASHG2017, Annerose Berndt, vice president of clinical genomics at University of Pittsburgh Medical Center, and Khalid Fakhro, director of genetics at Sidra Medical and Research Center in Qatar, outlined ambitious plans in large-scale genomics and precision medicine.

In my previous post, I described how Kari Stefansson started off this year’s ASHG breakfast session with a deep dive into deCODE’s toolbox and the powerful results the company has delivered.

Another of the renowned speakers at our “Genomes for Breakfast” session was Annerose Berndt, vice president of clinical genomics at UPMC (University of Pittsburgh Medical Center). She outlined UPMC’s ambitious plans in large-scale genomics and precision medicine. UPMC has a quite uniquely holistic role in underpinning the present and future healthcare of more than three million people in western Pennsylvania. It is an insurer, delivers healthcare through a rapidly growing network of dozens of hospitals, and conducts cutting-edge research in the life sciences and medicine, including through the University of Pittsburgh. It also has affiliated hospitals in nine countries apart from the U.S.

Last year, UPMC received one of the largest grants from the U.S. Precision Medicine Initiative and is investing in a large-scale genome sequencing effort that will both deliver patient care—through rare disease diagnostics and better-targeted cancer treatment—and create a major database for population-scale genomics research. Providing the integrated informatics, database, and tools for projects of such scale and combined clinical and research applications is what our platform does like no other, and we were very pleased to have UPMC present alongside and meet with our partners pursuing similar projects.

Closing out our population-focused breakfast we had the honor of hearing from our longtime collaborator Khalid Fakhro, director of genetics at our partner Sidra Medical and Research Center in Qatar. Sidra’s work, both on the Qatar Genome Programme and as the key maternity and pediatric hospital in Qatar, holds great promise for delivering higher-quality care to patients in Qatar and to advancing precision medicine around the world.

Echoing themes from Kari’s talk, Khalid outlined how Qatar’s population of 300,000, with its high consanguinity rates, is a fertile ground for identifying novel rare disease variants.

Leveraging data from 1,000 healthy Qataris and 600 families with rare disorders, Sidra has developed and published the first allelic map for any population in the Arab world. They are using WuXi NextCODE’s database and tools to drive forward with novel discoveries in a range of diseases, including congenital diarrhea and collagen disorders.

With the opening of Sidra’s hospital this year, and the integration of yet more data from the Qatar Genome Programme into our platform, Khalid emphasized that Qatar is well positioned to undertake not only a cutting-edge rare disease diagnostic testing program for pediatric patients but also drug target discovery. Much as deCODE has done with cardiovascular disease and numerous other conditions, the hope is to begin to analyze data for families and across the population in conditions such as type 2 diabetes. Such findings might well point to novel pathways that can be used to design treatments for those suffering from rare and common diseases alike.

I’ll also post soon about our second rare-disease focused breakfast session at ASHG: “Using NGS to diagnose rare disease—experiences from three continents.” Look for my next post about ASHG17.

Kari Stefansson led the group of renowned scientists and clinicians who presented at

Kari Stefansson led the first of two sessions focused on rare diseases at WuXi NextCODE’s annual “Genomes for Breakfast” series at the ASHG 2017 meeting in Orlando, Florida.

WuXi NextCODE’s annual “Genomes for Breakfast” sessions at the ASHG meeting in Orlando, Florida last week. Two of these sessions focused specifically on rare diseases, one from a population perspective and the other from a clinical perspective.

We were honored to host all our speakers, each of whom are leaders in their fields. They included some of our distinguished longstanding and newer partners as well as some of our own WuXi NextCODE colleagues. We had near-capacity crowds of some 300 attendees for each of the breakfasts. That setting provided an inspirational showcase of progress in understanding rare disease and also how WuXi NextCODE’s global platform can help accelerate this critical work.

The goal for us all is to enable rapid and affordable diagnosis of rare diseases in as many countries as possible. And WuXi NextCODE is uniquely positioned to support this endeavor.

As only he can do, Kari kicked the population session off with a deep dive into what he has gleaned from looking at the unique genetics resources he has amassed at deCODE genetics in Iceland over the past 20 years. These resources are of astonishing scale, including the directly sequenced whole genomes of nearly 50,000 Icelanders and 10,000 others; imputed whole genome from 400,000 Icelanders; and SNP data from nearly a million people around the world.

It was an even more notable event, because this year, Kari received the William Allen Award, the ASHG’s highest honor; so the full breadth of the work he and his deCODE colleagues have achieved was featured at several points in our events and elsewhere during the three-day meeting. Underscoring the reach and global outlook of deCODE’s work, Kari pointed out that deCODE is currently collaborating with over 250 international groups and 25 consortia. And his talk was particularly significant for us, because deCODE is not only the world’s first and largest population genomics effort, it is also the crucible in which our technology was forged and the inspiration for the large-scale genomics efforts that we partner with around the world.

Leading off the first breakfast session, entitled “Using Population Genomics to Understand Common and Rare Diseases,” Kari spoke to how deCODE has set out to capture and correlate not just variation in the genome and phenome, but also how genetic diversity itself is actually generated. He pointed out that you could look at life forms as entities whose function is to protect DNA, rather than the other way around. Understanding how DNA changes through generations is a mission-critical task for applying genomics to human health. Where are the sites of the most recombination? Under what circumstances and where are you most likely to see de novo mutations arise?

A pivotal 2002 paper from deCODE provided the world with the first high-resolution recombination map of the entire genome. That map was used to complete the assembly of the Human Genome Project (HGP): Before that paper was published, the HGP’s assembly was about 91% accurate. After the data from deCODE were incorporated, the map reached 99% accuracy.

One of Kari’s observations was that all physiological function is spread across populations in an essentially normal distribution. Looking at extremes—the rare phenotypes—is important, because they often reflect rare genetic factors that can reveal important information about biochemical pathways relevant not only to those carrying the mutations, but also to the rest of the population that has more common, but less extreme, perturbations in those pathways. In this sense, rare variant identification is important for public health in two ways: to diagnose and better treat those with rare disorders, and to find drug targets that can benefit all of us. Rare disease, it turns out, is a common challenge that we all need to meet together.

Kari was followed by two other outstanding speakers and WuXi NextCODE partners: University of Pittsburgh Medical Center’s Annerose Berndt and Khalid Fakhro of the Sidra Medical and Research Center in Qatar. I will provide details about their talks in my next post.

Genomic sequencing is key to developing drugs that can be repurposed alone or used in combination to treat new types of cancer.

One of the biggest new innovations in oncology is the use of combination therapies, and a recent FDA approval for a pair of drugs (dabrafenib and trametinib) for lung cancer underscores that. This is a big step forward and we expect to see many more combinations approved in the future.

But determining which are the right pairings for which particular tumors requires a lot of data. You have to figure out which patients carry particular mutations. That requires accurate testing tools, powerful analytics, and then reams of data to guide you. That’s one of the reasons WuXi NextCODE and others are so focused on building genomic databases and advanced genomic interpretation tools.

”Just collecting and sequencing a cohort is challenging,” says Jim Lund, Director of Tumor Product Development at WuXi NextCODE.  “But having detailed clinical information along with the samples is critical. That multiplies the value of your study.” This type of data creates a “two-way street,” explains Shannon T. Bailey, Associate Director of Cancer Genetics at WuXi NextCODE. “Genomic analysis doesn’t just tell you which drugs you should use, but which treatments will have no effect.”

So what was the latest step forward? Dabrafenib (Tafinlar®) and trametinib (Mekinist®) are now approved in combination for treatment of metastatic non-small cell lung cancer (NSCLC) for patients whose tumors have a specific alteration, called V600E, in the BRAF gene. About 1%-2% of lung tumors carry that mutation, which drives tumor growth and spread through the MAPK signaling pathway. The two drugs target this pathway but through different mechanisms. Dabrafenib is a BRAF inhibitor, and trametinib is a MEK inhibitor.

Perhaps 1%-2% doesn’t seem like a lot of patients. But three things are important here:

1. Lung cancer is a common and usually deadly disease, so a new approval for even a small number of patients will still have a lot of impact. We must chip away at the mortality rate for this condition however we can, even if the progress seems incremental.
2. Experts have a lot of hope that combination therapies will deliver the punch we’ve been looking for against many previously intractable cancers. That opens new paths for people who otherwise faced hopelessness.
3. The more patients receive these combinations, the more we can learn about what works, and why.

The data from today’s patients are a key part of what guide the treatments of tomorrow. This particular approval builds upon more than a decade of data from clinical trials. BRAF V600E has long been a prime suspect as a driver of several cancers. In 2014, the FDA approved this same combination of drugs for melanoma patients whose cancers were positive for the BRAF V600 mutation.

“Genomic sequencing has allowed researchers to identify specific genetic links between different cancers and then repurpose drugs developed for one cancer to treat another form of the disease,” says Lund. “This is data driving precision medicine.”

In tandem with the approval of the two-drug regimen for NSCLC, FDA also gave the OK for the Oncomine DX Target Test, a next-generation sequencing test that can detect BRAF V600E in tumor samples. It screens for multiple biomarkers including BRAF, ALK, ROS1, and EGFR genes. These can all help guide prescribing decisions.

“When we characterize lung tumors from patients, it’s a good idea to test the samples for all the changes that could be targeted by different drugs,” said Bruce E. Johnson of the Dana-Farber Cancer Institute, in a press release about this recent approval. Johnson co-led the clinical trials that were the basis for FDA’s approval of the combination therapy.

It’s also important to realize how difficult it is to carry out these trials. As I noted earlier, this is a very rare mutation. To recruit the 59 patients for the combination trial that led to this NSCLC approval, researchers screened about 6,000 patients. This feat alone represents a “major achievement that underlies the difficulties in completing such a trial,” the study researchers wrote, in an editorial that accompanied the paper about their findings.

These types of advances are spurring researchers to seek more links between established therapies and known mutations. “There are many additional drugs that can be repurposed alone or in combination to treat new types of cancer, and genomic sequencing will be key to both the research and clinical implementation of these new advances in cancer treatment,” says Lund.

WuXi NextCODE, meanwhile, is trying to accelerate progress by providing a comprehensive but user-friendly informatics suite that “allows clinicians to perform complex big data queries and interpretation on a case by case basis, and to annotate that data even if they lack formal computational training,” says Bailey.

Our vision is that eventually, clinicians and individuals all around the world will be deploying their genomes to contributing to our overall knowledge of “which drug—or, perhaps, which combination—works for which patient.”